Pretargeted radioimmunotherapy in the treatment of metastatic medullary thyroid cancer

被引：0
|
作者：
Kraeber-Bodere, F. [1 ,2 ]
Goldenberg, D. M. [3 ]
Chatal, J. F. [4 ]
Barbet, J. [2 ,4 ]
机构：
[1] Univ Hosp, Dept Nucl Med, Nantes, France
[2] Univ Nantes, INSERM, Canc Res Ctr, Nantes, France
[3] Ctr Mol Med & Immunol, Garden State Canc Ctr, Belleville, NJ USA
[4] Univ Nantes, Arronax Cyclotron, Nantes, France
来源：
CURRENT ONCOLOGY | 2009年 / 16卷 / 05期
关键词：
Pretargeted radioimmunotherapy; medullary thyroid cancer; calcitonin; BISPECIFIC ANTIBODY; PROGNOSTIC-FACTORS; BIVALENT HAPTEN; IMATINIB MESYLATE; FOLLOW-UP; CARCINOMA; SURVIVAL; CHEMOEMBOLIZATION; OPTIMIZATION; CALCITONIN;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：296 / 301
页数：6
相关论文
共 50 条
  • [31] Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response
    Valerio, Laura
    Bottici, Valeria
    Matrone, Antonio
    Piaggi, Paolo
    Viola, David
    Cappagli, Virginia
    Agate, Laura
    Molinaro, Eleonora
    Ciampi, Raffaele
    Tacito, Alessia
    Ramone, Teresa
    Romei, Cristina
    Elisei, Rossella
    ENDOCRINE-RELATED CANCER, 2020, 27 (02) : 97 - 110
  • [32] A Case Report of Sequential Use of a Yeast-CEA Therapeutic Cancer Vaccine and Anti-PD-L1 Inhibitor in Metastatic Medullary Thyroid Cancer
    Del Rivero, Jaydira
    Donahue, Renee N.
    Marte, Jennifer L.
    Gramza, Ann W.
    Bilusic, Marijo
    Rauckhorst, Myrna
    Cordes, Lisa
    Merino, Maria J.
    Dahut, William L.
    Schlom, Jeffrey
    Gulley, James L.
    Madan, Ravi A.
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [33] Chapter 9: Management of Medullary Thyroid Cancer
    Deshmukh, Anuja Dhananjay
    Thomas, Anand Ebin
    Abraham, Deepak Thomas
    JOURNAL OF HEAD & NECK PHYSICIANS AND SURGEONS, 2024, 12 (SUPPL 1): : S46 - S53
  • [34] Can procalcitonin be useful for medullary thyroid cancer?
    Kaczka, Krzysztof
    Mikosinski, Slawomir
    Fendler, Wojciech
    Jalocha-Kaczka, Anna
    Pomorski, Lech
    ENDOKRYNOLOGIA POLSKA, 2010, 61 (05) : 430 - 436
  • [35] Management of Medullary Thyroid Cancer: Patterns of Recurrence and Outcomes of Reoperative Surgery
    Papachristos, Alexander J.
    Nicholls, Laura E.
    Mechera, Robert
    Aniss, Ahmad M.
    Robinson, Bruce
    Clifton-Bligh, Roderick
    Gill, Anthony J.
    Learoyd, Diana
    Sidhu, Stan B.
    Glover, Anthony
    Delbridge, Leigh
    Sywak, Mark
    ONCOLOGIST, 2023, : 1064 - 1071
  • [36] Preoperative serum calcitonin may improve initial surgery for medullary thyroid cancer in patients with indeterminate cytology
    Jassal, Karishma
    Ravintharan, Nandhini
    Prabhakaran, Swetha
    Grodski, Simon
    Serpell, Jonathan W.
    Lee, James C.
    ANZ JOURNAL OF SURGERY, 2022, 92 (06) : 1428 - 1433
  • [37] The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer
    Fallahi, Poupak
    Ferrari, Silvia Martina
    Baldini, Enke
    Biricotti, Marco
    Ulisse, Salvatore
    Materazzi, Gabriele
    Miccoli, Paolo
    Antonelli, Alessandro
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (11) : 1109 - 1118
  • [38] Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer
    Viola, David
    Cappagli, Virginia
    Elisei, Rossella
    FUTURE ONCOLOGY, 2013, 9 (08) : 1083 - 1092
  • [39] Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced/metastatic medullary thyroid cancer
    Parikh, Rohan
    Hess, Lisa M.
    Esterberg, Elizabeth
    Bhandari, Naleen Raj
    Kaye, James A.
    THYROID RESEARCH, 2022, 15 (01)
  • [40] A Benign Medullary Thyroid Cancer
    Pishdad, Reza
    Rad, Mona Vahidi
    Cespedes, Lissette
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (01)
12345